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INTRODUCTION
In Japan, the estimated number of individuals with type 2 diabetes mellitus (T2DM) is approximately 7.1 million, which is the ninth largest prevalence in the world [1] . In recent years, the prevalence of T2DM in Japan has increased due to lifestyle changes, genetic predisposition, and an aging population [2, 3] . Most of the Japanese T2DM
patients are non-obese with an average body mass index (BMI) of 23-25 kg/m 2 , impaired insulin secretion plays a key role in the development of T2DM in these patients [4] .
Despite major advances in the management of T2DM and availability of a range of antidiabetic agents, evidence suggests that up to *60% of patients in Japan [5] fail to achieve the recommended target of glycosylated hemoglobin (HbA 1c ) levels \7.0% [6] .
Metformin is one of the commonly used oral antidiabetic agents (OADs) in Japan. Metformin improves blood glucose levels primarily by inhibiting hepatic glucose production and also improving insulin sensitivity in the liver and skeletal muscles [7] . However, due to the progressive nature of T2DM, long-term glycemic control is difficult to achieve with a single agent, thus often requiring addition of further agents. Addition of a dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor with metformin is beneficial due to their complementary mechanisms of action [8] .
Vildagliptin, a potent and selective DPP-4 inhibitor, increases the active levels of incretin hormones, glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP), thereby improving pancreatic a-and bcell sensitivity to glucose [9] . In large-scale clinical trials, vildagliptin improved glycemic control when given as monotherapy [10] or in combination with metformin [11] , sulfonylurea [12] , thiazolidinedione [13] or insulin [14] , with low risk of hypoglycemia and weight gain.
Vildagliptin 50 mg bid showed notable improvement in blood glucose levels and better tolerability compared with placebo [15] or voglibose [16] in Japanese patients with T2DM inadequately controlled on diet and exercise.
Combination therapy of vildagliptin with lowdose (500 mg bid) and high-dose (1,000 mg bid) metformin showed improved glycemic control compared with individual monotherapies in a large global study [17] . 
MATERIALS AND METHODS

Study Design
This was a 12-week, multicenter, randomized, Adverse events (AEs) and serious AEs (SAEs) were recorded at each visit, and were assessed for severity, duration, and suspected relationship to the study drug. Standard hematology, biochemistry, liver function tests, urinalysis, vital signs, and body weight were measured at the screening visit and at weeks 0, 4, 8, and 12. Electrocardiograms were recorded at screening and at the last study visit (week 12).
Fasting lipid profile was assessed at baseline and at the last study visit. All the patients were provided with a calibrated home glucose monitor and were instructed regarding its use. The patients were educated regarding hypoglycemic symptoms, possible triggers and were asked to record hypoglycemic event in a study diary. Hypoglycemia was defined as symptoms suggestive of hypoglycemia that was further confirmed by a self-monitored blood glucose measurement of \3.1 mmol/L.
The event was considered grade 1 if the patient was able to initiate self-treatment, and grade 2 if the patient required assistance of another person or hospitalization. All the laboratory assessments were performed at a central
Corporation, Japan).
Statistical Analysis
A total of 136 patients (68 patients per group) were to be randomized (1:1) to achieve a target 
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The study protocol was reviewed and approved by the Independent Ethics Committee/ Institutional Review Board at each center. All 
RESULTS
Patient Disposition and Baseline Characteristics
Of the 139 randomized patients (vildagliptin, n = 69; placebo, n = 70), 133 patients (95.7%) completed the study (Fig. 2) . The primary reasons for discontinuation in the study were AEs (3 patients) and protocol deviations (2 patients) (Fig. 2) . Patient demographics and baseline characteristics were comparable between the treatment groups ( 
Efficacy
The mean change in HbA 1c during the 12 weeks of treatment was consistently lower with vildagliptin than with placebo (Fig. 3a) . The overall adjusted mean change (AMD) ± SE in HbA 1c was -1.1 ± 0.06% in the vildagliptin group (baseline 8.0%) and -0.1 ± 0.06% in the placebo group (baseline 8.0%), with a statistically significant between-treatment difference of -1.0 ± 0.09% (P\0.001) in favor of vildagliptin (Fig. 3b) . Vildagliptin also showed statistically significant reductions from baseline in HbA 1c for subpopulations of patients receiving metformin 250 mg bid and 500 mg bid ( Vildagliptin showed sustained reduction in FPG over placebo during the 12 weeks of treatment (Fig. 4a) . The AMD ± SE in FPG from baseline to endpoint was greater in patients receiving vildagliptin (-1.7 ± 0.16 mmol/L) compared with those receiving placebo (-0.1 ± 0.16 mmol/L), with a between-treatment difference of -1.6 ± 0.22 mmol/L (P\0.001) (Fig. 4b) .
Safety
The overall proportion of patients experiencing AEs was comparable between the vildagliptin (44.1%) and placebo (41.4%) groups. The most commonly reported AE by primary SOC was ''infections and infestations'' (13.2% for vildagliptin and 14.3% for placebo). The most frequently reported AE (C2% in any group) by PT was ''nasopharyngitis'' (7.4% for vildagliptin and 5.7% for placebo) ( Table 5 ). While incidence of AEs was low across PTs in both the treatment groups, ''amylase increased'' was reported in more patients with vildagliptin (4 patients; 5.9%) than with placebo (1 patient; 1.4%) and anemia was more frequent with placebo (3 patients; 4.3%) than with vildagliptin (0 patient). All the events of increased amylase levels were classified as mild and clinically asymptomatic. All the reported AEs were mild or moderate in severity. The incidence of AEs suspected to be related to the study drug was slightly higher in the vildagliptin group than in the placebo group (16.2% vs. 10.0%). One patient in the vildagliptin group and two patients in the placebo group discontinued the study. No SAEs were reported in the vildagliptin group, whereas one SAE of myocardial infarction was reported in the placebo group. There were no deaths during the study. No hypoglycemic events were reported in the study. There was and daily dose of metformin in this study, the between-treatment difference (-1.0%) seen was consistent with the findings previously reported in a predominantly Caucasian population, where vildagliptin-treated patients showed a decrease in HbA 1c of 1.1% vs. placebo over 24 weeks of treatment [11] . Moreover, the reduction in HbA 1c levels reported with vildagliptin therapy was consistent with other DPP-4 inhibitors with different study designs in Japanese population [18] [19] [20] . These findings indicate that vildagliptin is effective in Japanese patients with T2DM when added to metformin monotherapy. Further, vildagliptin showed statistically significant and clinically meaningful reduction [6] . The responder rate (\7.0%) was higher than that reported in a predominantly Caucasian population (55.4%) [11] . Over half of the population (57.4%) achieved an HbA 1c reduction of C1.0%, and 86.8% of patients reported a reduction of C0.5% in the vildagliptin group.
Vildagliptin showed statistically significant reduction in FPG levels vs. placebo (P\0.001) as add-on to metformin monotherapy after 12 weeks of treatment. The decrease in FPG could be attributed to increased active levels of GLP-1 upon twice-daily administration of vildagliptin 50 mg, which enhances insulin secretion and suppresses glucagon levels BL baseline, BMI body mass index, FPG fasting plasma glucose, HbA 1c glycosylated hemoglobin, SE standard error relative to glucose levels, in turn decreasing the endogenous glucose production overnight [21] .
Overall, vildagliptin added to metformin was safe with no new safety findings observed in Japanese patients with T2DM. The observed safety profile was similar with previously reported 52-week safety study of vildagliptin add-on to metformin in Japanese patients with T2DM [22] , long-term study of vildagliptin add-on to metformin in a predominantly Caucasian population [23] , and safety pooled analysis of vildagliptin studies of C12 to C104 weeks duration [24] . Four patients in the vildagliptin group and one patient in the placebo group reported clinically asymptomatic mild elevations of amylase and/or lipase; however, none of these cases were considered as an AE of acute pancreatitis by the investigators. Similar to the previously reported studies [25] , treatment with vildagliptin as add-on to metformin confirmed its weight neutrality in Japanese patients.
There were no incidences of hypoglycemia reported in the study. Absence of hypoglycemic events in the vildagliptin group, in spite of lower mean baseline FPG and HbA 1c levels than the global study [11] , confirms the glucose-dependent action of vildagliptin. This is consistent with the results from a previously reported large pooled analysis of global safety data, which showed that vildagliptin, as monotherapy or in combination with metformin, thiazolidinedione, or sulfonylurea, is associated with fewer hypoglycemic events compared with comparators [24] .
The notable benefit observed in improving HbA 1c levels confirms the complementary mechanism of action of vildagliptin and metformin in Japanese patients with T2DM. Metformin increases the plasma concentration of incretin hormones and enhances the effects of DPP-4 inhibition on the increase of intact GLP-1, which might explain the improved efficacy of vildagliptin in combination with metformin [26] .
In conclusion, vildagliptin 50 mg bid as addon to metformin is effective in reducing HbA 1c and FPG levels without any tolerability issues and hypoglycemia in Japanese patients with T2DM inadequately controlled on metformin monotherapy.
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